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Abstract: Invasive Aspergillus infection (IA) is a significant cause of morbidity in lung 
transplantation (LT).  However, its optimal prophylaxis is unclear.  We routinely 
administer itraconazole (ITCZ) prophylaxis to all patients undergoing LT.  In this study, 
we retrospectively evaluated the duration of prophylaxis and risk factors of IA.  
Among 30 adult patients who underwent LT, 5 patients developed IA.  All patients 
with IA stopped ITCZ treatment within 1 year.  At least 1-year of itraconazole 
prophylaxis is essential for the prevention of IA.  Cytomegalovirus infection, renal 
replacement therapy and tracheotomy were risk factors for IA.   
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Introduction:  
Invasive Aspergillus infection (IA) is a major cause of morbidity and mortality in lung 
transplantation (LT) patients (1).  IA, occurring in 19-49% [Pappas PG, Alexander BD, 
Andes DR, Hadley S, Kauffman CA, Freifeld A, et al. Invasive fungal infections among 
organ transplant recipients: results of the Transplant-Associated Infection Surveillance 
Network (TRANSNET). Clin Infect Dis 2010 Apr 15;50(8):1101-1111]/ [Tofte N, 
Jensen C, Tvede M, Andersen CB, Carlsen J, Iversen M. Use of prophylactic 
voriconazole for three months after lung transplantation does not reduce infection with 
Aspergillus: a retrospective study of 147 patients. Scand J Infect Dis 2012 
Nov;44(11):835-841.]  LT patients, is responsible for deaths (2)[ Felton TW, Roberts 
SA, Isalska B, Brennan S, Philips A, Whiteside S, et al. Isolation of Aspergillus species 
from the airway of lung transplant recipients is associated with excess mortality. J Infect 
2012 Oct;65(4):350-356.].  Though prophylaxis is crucial, the optimal strategy for 
preventing IA is uncertain (3).  Itraconazole (ITCZ) has been reported to exhibit 
significant activity against Aspergillus spp. and other fungi (4).  At Kyoto University 
Hospital in Japan, we administered ITCZ prophylaxis to all patients undergoing LT.  
All patients were administered 200–400mg ITCZ as 1% oral solution (Itrizole®, 
Janssen Pharmaceutica).  Serum ITCZ concentrations, i. e. itraconazole and 
hydroxyitraconazole (ITCZ plus OH-ITCZ) were measured once a week after 
administration.  Therapeutic drug monitoring (TDM) of ITCZ was performed in at 
least one sample from each patient.  There is little consensus on the duration of 
prophylaxis.  In our hospital, the doctor in charge decided the dosing period.  
 
Methods: 
In this research, adult LT patients transplanted from 2008 to 2012 at Kyoto University 
Hospital were retrospectively studied.  All lung recipients were followed clinically by 
a team of physicians (respiratory surgeons, anesthesiologist, infectious disease 
physicians, cardiologists)  They participated in the pre-transplant evaluation and in 
post-transplant management of patients.  Postoperative immunosuppression consisted 
of triple-drug therapy with cyclosporine or tacrolimus, azathioprine or mycophenolate 
mofetil, and corticosteroids. [H. Date, M. Aoe, Y. Sano, I. Nagahiro, K. Miyaji, K. Goto 
et al. Improved survival after living-donor lobar lung transplantation J Thorac 
Cardiovasc Surg, 28 (2004), pp. 933–940] Episodes of acute rejection were treated with 
high doses of methylprednisolone. 
All patients received routine antifungal prophylaxis with micafungin intravenously and 
ITCZ enterally following transplantation.  After serum ITCZ concentrations reached 
  
500-1000 ng/ml, we stopped administering micafungin.  We compared patients 
suffering IA with patients free from IA with more than 1 year observational time after 
transplantation.  
Sixteen female and 14 male patients (age range 26–62 years, mean 45. 7 years) were 
included.  We deﬁned LT patients with proven, probable or possible IA based on 
European Organization for the Research and Treatment of Cancer/Mycoses Study 
Group criteria (5).  The classification of Aspergillus infection is based on the type of 
the host-fungus relationship.[ Karnak D, Avery RK, Gildea TR, Sahoo D, Mehta AC. 
Endobronchial fungal disease: an under-recognized entity. Respiration. 
2006;74(1):88–104.]   
Among 30 patients, 21 patients underwent double lung transplantation (DLT) and 9 
underwent single lung transplantation (SLT).  Four patients (13%) acquired 
cytomegalovirus (CMV) infection, 11 patients (37%) developed acute rejection and 12 
patients (40%) underwent tracheotomy.  During 5 years, 5 patients developed 
Aspergillus infection (IA group), including 2 patient with proven and 3 with probable 
(Table 1).   
Twenty-five patients without IA were assigned as the control group (C group).  
The demographic data of the patient were analyzed and described using mean and 
median for continuous variables.  Comparisons of continuous data were made using 
the non-parametric Mann–Whitney test.  Two-value comparisons of categorical data 
were made using the chi-square test or Fisher’s exact test.  A P value of < 0.05 was 
considered statistically signiﬁcant. 
 
 
Results: Five patients developed IA during observational period.   IA patients all 
suffered invasive Aspergillus tracheobronchial infections, which was the most common 
form of IA [ScientificWorldJournal. 2011; 11: 2310–2329. Tracheobronchial 
Manifestations of Aspergillus Infections].  All cases had no obvious other organ 
involvement.  The lung was the primary focus of IA. 
All the 5 IA cases occurred more than 6 months after surgery.  The median time to 
onset after transplantation in the present study was 307 days.  Case 1-3 and 5 
developed IA after discontinuing ITCZ prophylaxis.  However, case 4 developed IA 
despite ITCZ administration, whose concentration was more than 1000 ng/ml at the 
time of IA onset.  Under careful monitoring, immunosuppressants trough level were 
within limits of protocol [H. Date, M. Aoe, Y. Sano, I. Nagahiro, K. Miyaji, K. Goto et 
al. Improved survival after living-donor lobar lung transplantation J Thorac Cardiovasc 
  
Surg, 28 (2004), pp. 933–940] over an entire period. 
Graft of case 2 was loss because of IA and she had a re-transplantation.  Case 3 was 
died because of chronic rejection, gastroparesis and combination of various factors.  IA 
cause directly leading to death in case 5.  
During prophylaxis, mean ITCZ concentrations were 878 ± 632 ng/ml in the IA group 
and 1059 ± 871 ng/ml in the C group (Table 2).  There was no significant difference 
between IA group and C group.   
 
Discussion: 
IA occurred 5 patients (16.7%) which rate is relatively low. [Pappas PG, Alexander BD, 
Andes DR, Hadley S, Kauffman CA, Freifeld A, et al. Invasive fungal infections among 
organ transplant recipients: results of the Transplant-Associated Infection Surveillance 
Network (TRANSNET). Clin Infect Dis 2010 Apr 15;50(8):1101-1111]/ [Tofte N, 
Jensen C, Tvede M, Andersen CB, Carlsen J, Iversen M. Use of prophylactic 
voriconazole for three months after lung transplantation does not reduce infection with 
Aspergillus: a retrospective study of 147 patients. Scand J Infect Dis 2012  
According to a previous study, IA developed a median of 96 days after transplantation, 
with 51% occurring within 90 days and 72% occurring within 180 days after 
transplantation (6).  In our hospital, we think that antifungal prevention is partly 
effective, and as a consequence, the onset rate is comparatively low and the onset time 
is late.  Among 30 patients in this study, 9 patients were administrated ITCZ for more 
than 1 year.  None of them (9 patients) were diagnosed with IA.  Twenty one patients 
stopped ITCZ administration within 1 year and 5 (24%) patients developed IA.   
We suppose at least 1 year prophylaxis is necessary.  Because of a small sample size 
and short observation period, further investigation is needed to decide adequate duration 
of prophylaxis.   
Next, we examined the risk factors of IA in LT patients using univariate analysis (Table 
2).  Factors associated with IA development were CMV infection, renal replacement 
therapy and tracheotomy.  Because of the small sample size, there was no significant 
difference, but advanced age and acute rejection tended to be associated with IA 
development (Table2), which was compatible with a previous report (7).  SLT did not 
suppose a significant risk for IA in our study.  It is probably because none of our 
patients had airway colonization with Aspergillus before transplantation (data not 
shown) and were not diagnosed with cystic fibrosis, which is a predictive factor of 
Aspergillus colonization (8).  
It is convincible that Aspergillus was acquired after stopping ITCZ because all the 5 IA 
  
patients never had positive sputum or BAL cultures for Aspergillus spp. before 
developing IA and their lungs are constantly exposed to Aspergillus spores in ambient 
air.  On the other hand, Considering that Aspergillus spp. were generally isolated from 
35% of LT recipients and anastomotic region is a vulnerable site, [ [ Felton TW, Roberts 
SA, Isalska B, Brennan S, Philips A, Whiteside S, et al. Isolation of Aspergillus species 
from the airway of lung transplant recipients is associated with excess mortality. J Infect 
2012 Oct;65(4):350-356.]] another possible mechanism is distant activation of disease, 
as a result to ineffective early prophylaxis.  Either, both or more mechanism are 
responsible for IA, but that is not confirmed.  Further studies are required to 
investigate potential mechanisms of IA after LT. 
 
Optimal prophylaxis strategies for lung transplant recipients remain poorly defined. 
Different drugs are used throughout the world [Husain S, Zaldonis D, Kusne S, Kwak 
EJ, Paterson DL, McCurry KR. Variation in antifungal prophylaxis strategies in lung 
transplantation. Transplant Infectious Disease. 2006;8(4):213–218] 
Echinocandins, nebulized amphotericin B, oral voriconazole, or itraconazole, alone or in 
combinations ar included. [Husain S, Zaldonis D, Kusne S, Kwak EJ, Paterson DL, 
McCurry KR. Variation in antifungal prophylaxis strategies in lung transplantation. 
Transplant Infectious Disease. 2006;8(4):213–218][Zaragoza R, Pemán J, Salavert M, et 
al. Multidisciplinary approach to the treatment of invasive fungal infections in adult 
patients. Prophylaxis, empirical, preemptive or targeted therapy, which is the best in 
the different hosts? Therapeutics and Clinical Risk Management. 2008;4(6):1261–1280] 
The echinocandins may be potentially effective agents for prevention of IA, but their 
dosage form, intravenous injection, is not suitable after leaving hospital.  Recent study 
showed that use of prophylactic voriconazole for LT patients does not reduce IA and its 
side effect is troublematic.[ Tofte N, Jensen C, Tvede M, Andersen CB, Carlsen J, 
Iversen M. Use of prophylactic voriconazole for three months after lung transplantation 
does not reduce infection with Aspergillus: a retrospective study of 147 patients. Scand 
J Infect Dis 2012 Nov;44(11):835-841. ]  Now that the use of aerosolized medications 
may significantly reduce their toxic systemic effects and potential drug interactions, 
they are an attractive option [ Solé A. Invasive fungal infections in lung transplantation: 
role of aerosolised amphotericin B. International Journal of Antimicrobial Agents. 
2008;32(2):S161–S165].  We began to administer nebulised amphotericin B with ITCZ.  
We will evaluate combination therapy of nebulized amphotericin B and ITCZ including 
therapy duration.    
 
  
In conclusion, IA remains a devastating disease in lung transplant patients.  We need to 
reconsider the duration of ITCZ prophylaxis, we think that a prophylactic 
administration for at least 1 year after transplantation would be reasonable especially to 
patients considered to be at high risk of IA.  CMV infection, renal replacement 
therapy and tracheotomy were risk factors for IA.   
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Table 1: Clinical characteristics of the 4 patients suffering IA 




Pt.  no. : Patient number, M: Male, F: female; R: right, BO: bronchiolitis obliterans; 
HSCT: hematopoietic stem cell transplantation, IPF: idiopathic pulmonary fibrosis, 
COPD: Chronic Obstructive Pulmonary Disease, RRT: renal replacement therapy, POD: 
postoperative day, LDLT: Living donor lung transplantation, DDLT: deceased donor 
lung transplantation 
*: Case 3 developed IA though he was administered ITCZ at that time.   He quitted 























































































Table 2：Comparison of Invasive Aspergillus infection group to Control group 
 
 IA group (5) C group(25) P value 
Age(years):Mean 51. 4 44. 2 0. 19a 
Gender: Male 2(40%) 12(48%) 0. 74 
Transplantation 
type: DLT 
4(80%) 17 (68%) 0. 59 
Immunosupression 
before operation 
2(40%) 10(40%) 1 
acute rejection 3(60%) 8 (32%) 0. 23 
CMV infection 3(60%) 1(4%) 0. 00071 
RRT 1(20%) 0(0%) 0. 023 
tracheotomy 4(80%) 8(32%) 0. 046 
ITCZ use more than 
6 months 
1(20%) 14(56%) 0. 14 
ITCZ use more than 
1 year 
0(0%)  9(36%) 0. 11 
Duration mean 96. 2(7-166) 424(35-1556)  0. 13a 
ITCZconcentration 878 ± 632 ng/ml 1059 ± 871 ng/ml 0. 61a 
 
CMV infection, RRT and tracheotomy were risk for IA.   
IA:Invasive Aspergillus infection  
DLT:double lung transplant, 
RRT: renal replacement therapy 
CMV: Cytomegalovirus 
 a Mann-Whitney test 
 
 
 
 
 
 
 
 
 
 
 
